Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER).

What Was Tested

The paper reports a study of NAD+, published as a randomized controlled trial.

Antioxidants may have positive impact on diabetic polyneuropathy (DPN), presumably due to alleviation of oxidative stress.

ClinicalTrials.gov Registry (NCT04649203; Unique Protocol ID: CTF-III-DM-2019).

Who Took Part

PubMed tags the participants as both men and women.

In a double-blind, placebo-controlled clinical trial, men and women aged 45-74 years with type 2 diabetes and symptomatic DPN, with initial Total Symptom Score (TSS) ˃5, were randomized into experimental (n=109) or placebo (n=107) group.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with NAD+ could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Antioxidants, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Inosine, Niacinamide, Riboflavin and Succinic Acid.

Author keywords: Diabetes Complications.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of NAD+.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (BMJ open diabetes research & care), a journal based in England.

More context: the NAD+ compound page, all human trials.